戻る Agenda
LS30: Paradigm Shift of Clinical Trial Site Costs ~Effort to Address the Diversifying Changes in Clinical Trial Design~
Session Chair(s)
Kenji Udo
Group Lead of Clinical Operations, Pfizer R&D Japan G.K., Japan
Speaker(s)
Toshiyuki Okada
Director, Clinical Operating Model, Strategic Business Operations and Execution, Astellas Pharma Inc., Japan
Keiichi Inaizumi, MSC
Clinical Study Innovation Lead, Clinical Project Management Group, Pfizer R&D Japan, Japan
